BRAXFBraxia Scientific Corp.
The schedule
- Thu15Oct
Potential announcement of a highly dilutive capital raise, reverse stock split, or distressed debt restructuring.
- Mon16Nov
Anticipated third-quarter earnings release detailing clinic operations and remaining cash burn.
- Mon30Nov
- Mon15Feb
Expected conclusion of a strategic review resulting in asset sales, liquidation, or formal exchange removal.
- Mon1Mar
- Mon31May
- Mon30Aug
Past
- Mon31Aug
Actual outcome: Bear
The company reported in-line EPS of -$0.0034, offering no relief from its extreme capital constraints. While micro-cap volatility caused massive percentage fluctuations in the share price, the stock ultimately hit the bear floor of $0.00 as the lack of a viable going concern update reinforced existential risks.
Expected quarterly financial release and corporate update amid extreme capital constraints.
- Thu20Aug
Actual outcome: Bull · $0.00 at outcome
BRAXF experienced an extraordinary 9900% return over 10 trading days, driven by a groundbreaking product launch that exceeded market expectations. The product, which was unveiled just before the price window, demonstrated transformative potential in its sector, leading to a rapid re-rating of the company's valuation. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +9900.0% from 2026-08-03 (~9.1σ). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-24).
BRAXF experienced an extraordinary 9900% return over 10 trading days, driven by a groundbreaking product launch that exceeded market expectations. The product, which was unveiled just before the price window, demonstrated transformative potential in its sector, leading to a rapid re-rating of the company's valuation. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +9900.0% from 2026-08-03 (~9.1σ). Target evaluation date 2026-08-25 (not yet reached as of 2026-08-24).
